HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

somatoKine

an IGF-1-BP3 fusion protein that may be useful in treating growth hormone insensitivity syndrome

Networked: 4 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Recombinant Proteins: 2754
    - Recombinant Fusion Proteins: 333
      - somatoKine: 4

Experts

1.	Avila A, Alejandra: 1 article (01/2006)
2.	Barrera P, Alvaro: 1 article (01/2006)
3.	Cassorla G, Fernando: 1 article (01/2006)
4.	Fuentes G, Ariel: 1 article (01/2006)
5.	Gunn, Ronald D: 1 article (01/2006)
6.	Iñíguez V, Germán: 1 article (01/2006)
7.	Mericq G, Verónica: 1 article (01/2006)
8.	Román R, Rossana: 1 article (01/2006)
9.	Salazar C, Teresa: 1 article (01/2006)
10.	Kemp, Stephen F: 1 article (04/2005)

Related Diseases

1.	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/01/2003 - "In January 2003, Insmed announced positive results from a double-blind, placebo-controlled, dose-ranging study of SomatoKine in adolescent patients with type 1 diabetes mellitus redolescent patients with type 1 diabetes mellitus receiving insulin therapy. "
2.	Type 2 Diabetes Mellitus (MODY) 01/01/2003 - "Insmed is holding a US patent (expires in 2019) for the use of SomatoKine in the treatment of both type 1 and type 2 diabetes mellitus." 04/01/2003 - "SomatoKine, a recombinant fusion of insulin-like growth factor-1 and its binding protein, BP-3, is being developed by Insmed (formerly Celtrix Pharmaceuticals) for the potential treatment of growth hormone insensitivity syndrome (GHIS), and as a potential injectable insulin sensitizer for the management of type 1 and type 2 diabetes in patients who are less sensitive to insulin therapy. "
3.	Laron Syndrome (Syndrome, Laron) 04/01/2003 - "SomatoKine, a recombinant fusion of insulin-like growth factor-1 and its binding protein, BP-3, is being developed by Insmed (formerly Celtrix Pharmaceuticals) for the potential treatment of growth hormone insensitivity syndrome (GHIS), and as a potential injectable insulin sensitizer for the management of type 1 and type 2 diabetes in patients who are less sensitive to insulin therapy. "
4.	Hypoglycemia (Reactive Hypoglycemia) 04/01/2005 - "SomatoKine appears to have a longer half-life in patients with GHIS than unbound IGF-I and fewer adverse events (including hypoglycemia) have been reported when administered to patients with diabetes." 04/01/2005 - "SomatoKine was developed to prolong the half-life and to counteract acute adverse events (particularly hypoglycemia) associated with IGF-I administration. "
5.	Growth Disorders 04/01/2005 - "SomatoKine: is there a use in treating growth disorders?"

Related Drugs and Biologics

1.	Insulin (Novolin)
2.	Insulin-Like Growth Factor I (IGF-1)
3.	Insulin-Like Growth Factor Binding Protein 3
4.	Carrier Proteins (Binding Protein)

Related Therapies and Procedures

1.	Therapeutics
2.	Injections